<DOC>
	<DOCNO>NCT00002435</DOCNO>
	<brief_summary>To investigate safety thymic humoral factor ( THF gamma 2 ) , effect HIV load base least 75 percent decrease HIV quantitative PCR RNA copies/ml , persistence administer combination antiretroviral nucleoside derivative ( zidovudine ; AZT ) . To assess effect THF gamma 2 T-cells , quality life , progression disease .</brief_summary>
	<brief_title>A Study Thymic Humoral Factor ( THF Gamma 2 ) HIV-Infected Patients</brief_title>
	<detailed_description>All patient receive 12 week AZT randomize self-administer one two dos THF gamma 2 placebo 15 consecutive day twice weekly additional 50 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Thymic humoral factor gamma 2</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AZT another antiretroviral agent ( marketed investigational Treatment IND ) . Primary prophylaxis Pneumocystis carinii pneumonia ( PCP ) , toxoplasmosis , Mycobacterium aviumintracellulare ( MAI ) patient 's CD4 count decrease &lt; 200 cells/mm3 . Other market drug require . Patients must : HIV seropositivity either asymptomatic persistent generalize lymphadenopathy ( PGL ) . No history symptom Category B C 1993 Case Definition , oral candidiasis follow previous broadspectrum antibiotic therapy . Mean CD4 200500 cells/mm3 . HIV1 positive PCR RNA . Ability selfadminister study drug IM injection . Ability tolerate AZT 600 mg daily first 8 week runin period ( AZT naive ) OR tolerate AZT &gt; = 500 mg daily least 3 month 12 month prior randomization . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy . Hematuria . Proteinuria &gt; 1+ . Concurrent Medication : Excluded : Nonantiretroviral agent know suspected activity HIV . Investigational new drug antiretroviral agent distribute Treatment IND . Patients follow prior condition exclude : Myositis within past 6 month . Prior Medication : Excluded : Experimental therapy , include interleukin2 , interferon , erythropoietin , filgrastim nucleoside within 6 week prior study entry . Prior antiretroviral therapy ( AZTnaive patient ) . Prior Treatment : Excluded within 6 week prior study entry : Blood transfusion blood product . Active alcoholism , drug abuse , mental psychiatric problem sufficient prevent adequate compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1998</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>thymic humoral factor gamma 2</keyword>
</DOC>